74 results
Page 2 of 4
8-K
EX-99.1
mh9za4s52
23 Jun 23
Entry into a Material Definitive Agreement
9:16am
8-K
EX-99.1
0dh4g2hs
22 Jun 23
Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
5:20pm
8-K
EX-99.2
cpt0nuc3g5xxdcll
3 Nov 22
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
7:02am
8-K
EX-99.1
ivqafqxw v2qy10
6 Sep 22
Regulation FD Disclosure
5:01pm
8-K
EX-99.2
apnmgf0 6y
4 Aug 22
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
6:01am
424B5
z7kss63l40
20 May 22
Prospectus supplement for primary offering
4:02pm
424B5
kyxyz8b
6 May 22
Prospectus supplement for primary offering
7:15am
8-K
EX-99.2
d119w6yqe0jyhm5e6
5 May 22
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
6:34am
8-K
EX-99.3
n5exij
12 Apr 22
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD
6:02am
8-K
EX-99.2
fxwcs2
8 Mar 22
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Program Updates
7:04am
424B5
iwr1u71hv klhb
9 Feb 22
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
pemgh
5 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
y4pkwg
9 Sep 21
Regulation FD Disclosure
7:00am